CAR-T细胞免疫疗法是Chimeric Antigen Receptor T-Cell Therapy（嵌合抗原受体T细胞疗法）的简称，其治疗原理是通过对嵌合抗原受体进行基因工程改造，以促进T淋巴细胞表达，从而实现肿瘤细胞靶向抗原识别并杀伤肿瘤细胞，起到治疗相应的血液系统恶性肿瘤的效果。在免疫疗法出现之前，化疗、放疗和外科手术是最传统的癌症治疗方法...
Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration;...
1. **CART疗法(Chimeric Antigen Receptor T-Cell Therapy)**: - **原理比喻**:想象T细胞是身体里的“抗癌警察”,但有些时候它们无法有效识别并抓捕“坏人”(癌细胞)。CART疗法就像给T细胞戴上一副高科技的“眼镜”,使它们能精准识别癌细胞,并赋予更强的战斗力。 - **具体解释**:科学家通过基因工程技术,将...
https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy Section Editor: Howard (Jack) West, MD. The JAMA Oncology Patient Page is a public service of JAMA Oncology. The information and recommendations appearing on this page are appropriate in mo...
Infusion of T cells engineered to express chimeric antigen receptors (CARs) that target B cells has proven to be a successful treatment for B cell malignancies. This success inspired the development of CAR T cells to selectively deplete or modulate the aberrant immune responses that underlie autoim...
Chimeric antigen receptor T-cell therapy or CAR-T-cell therapy in short, which is developed by a company in Jiangning High-tech Zone, Nanjing, has been approved for marketing by the FDA of the USA. The first CAR-T-cell therapy product independently developed by China and to be marketed ov...
Chimeric Antigen Receptor T-Cell Therapy The field of therapeutic T cell engineering has gained significant attention in recent times because of the notable achievements of CD19 (chimeric antigen receptor) CAR treatment. Chimeric antigen receptors (CARs) are manufactured receptors designed to alter the...
CAR-T(Chimeric Antigen Receptor T cell),即嵌合抗原受体(CAR)T细胞,是一种新的细胞疗法,从患者身上获取自体T细胞并进行基因修饰以表达嵌合抗原受体。这些受体由细胞外的scFv组成,该scFv被设计成与高特异性靶标结合,以及由共刺激结构和T细胞受体(TCR)zeta链组成细胞内部分[1,2]。这些修饰的目的是产生一种T细胞,当...
Specifically, transduced T cells exhibited a 0.46 higher (P=0.053) and a 0.39 lower (P=0.142) rate of TLA among patients 16 years of age or older and those younger than 16 years of age, respectively.Conclusions:We observed CAR T-cell therapy was associated with greater biological aging as...
嵌合抗原受体(Chimeric antigen receptor,CAR)修饰的T细胞治疗在治疗血液肿瘤领域取得令人欣喜的治疗效果,尤其是抗CD19 CART细胞在治疗B细胞恶性肿瘤患者时显著提高了其临床结局。抗CD19和抗CD20 CART在治疗复发难治性B细胞急性淋巴细胞白血病B-ALL和非霍奇金淋巴瘤NHL的临床试验中已广泛开展,并显示出了一定的有效性。